Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers:: a case-control study

被引:73
|
作者
Narod, Steven A.
Lubinski, Jan
Ghadirian, Parviz
T Lynch, Henry
Moller, Pal
Foulkes, William D.
Rosen, Barry
Kim-Sing, Charmaine
Isaacs, Claudine
Domcheck, Susan
Sun, Ping
机构
[1] Univ Toronto, Ctr Res Womens Hlth, Toronto, ON M5G 1N8, Canada
[2] Pomeranian Med Univ, Szczecin, Poland
[3] Univ Montreal, Cent Hosp Univ Montreal Hotel Dieu, Epidemiol Res Unit, Montreal, PQ, Canada
[4] Creighton Univ, Sch Med, Dept Prevent Med & Publ Hlth, Omaha, NE USA
[5] Norwegian Radium Hosp, Dept Canc Genet, Oslo, Norway
[6] McGill Univ, Dept Oncol & Human Genet, Program Canc Genet, Montreal, PQ, Canada
[7] Univ Hlth Network, Dept Gynecol, Toronto, ON, Canada
[8] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[9] Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA
[10] Univ Penn, Dept Med, Philadelphia, PA 19104 USA
[11] Univ Penn, Dept Genet, Philadelphia, PA 19104 USA
来源
LANCET ONCOLOGY | 2006年 / 7卷 / 05期
关键词
D O I
10.1016/S1470-2045(06)70624-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Screening mammography is associated with a small dose of radiation to the breast, and women with increased genetic risk might be particularly sensitive to the DNA-damaging effects of ionising radiation. We aimed to assess whether exposure to ionising radiation through mammography screening was associated with risk of breast cancer in BRCA1 or BRCA2 mutation carriers. Methods We identified 1600 cases of breast cancer and 1600 controls without breast cancer who were matched for BRCA mutation, date of birth (within 1 year), and country of residence from an international registry of BRCA1 and BRCA2 mutation carriers. We used a questionnaire to inquire about whether participants had ever had screening mammography, and, if so, the age at which they first had the procedure. Results We found no association between ever having screening mammography and risk of breast cancer (odds ratio [OR] 1.03 [95% CI 0.85-1.25], adjusted for parity, oral-contraceptive use, ethnic origin, and bilateral oophorectomy). The association was much the same for BRCA1 mutation carriers and BRCA2 mutation carriers (1.04 [0.84-1.29] vs 1.06 [0.67-1.66], respectively, adjusted for parity, oral-contraceptive use, ethnic origin, and bilateral oophorectomy). Interpretation These findings do not lend support to the idea that exposure to ionising radiation through routine screening mammography contributes substantially to the burden of breast cancer in BRCA1 and BRCA2 mutation carriers. Prospective studies are needed to confirm the results of this initial report, and, where possible, these studies should assess a more appropriate endpoint of total exposure.
引用
收藏
页码:402 / 406
页数:5
相关论文
共 50 条
  • [21] SECOND BREAST CANCER RISK IN BRCA1 AND BRCA2 MUTATION CARRIERS PATIENTS
    Palazzo, A.
    Iacovelli, R.
    Trenta, P.
    Sidoni, T.
    Ricevuto, E.
    Naso, G.
    Giannini, G.
    Gulino, A.
    Cortesi, E.
    De Marchis, L.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 33 - 33
  • [22] Risk Management for BRCA1/BRCA2 Mutation Carriers Without and With Breast Cancer
    Mainor, C. B.
    Isaacs, C.
    [J]. CURRENT BREAST CANCER REPORTS, 2020, 12 (02) : 66 - 74
  • [23] Vitamin D, calcium supplement use and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study.
    Guyonnet, Emma
    Kim, Shana J.
    Zhang, Cindy X.
    McCuaig, Jeanna
    Armel, Susan
    Narod, Steven A.
    Kotsopoulos, Joanne
    [J]. CANCER RESEARCH, 2022, 82 (12)
  • [24] Folic acid supplement use and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a case–control study
    Shana J. Kim
    Cindy X. W. Zhang
    Rochelle Demsky
    Susan Armel
    Young-In Kim
    Steven A. Narod
    Joanne Kotsopoulos
    [J]. Breast Cancer Research and Treatment, 2019, 174 : 741 - 748
  • [25] Risk Management for BRCA1/BRCA2 Mutation Carriers Without and With Breast Cancer
    C. B. Mainor
    C. Isaacs
    [J]. Current Breast Cancer Reports, 2020, 12 : 66 - 74
  • [27] Oral contraceptives and breast cancer risk in BRCA1 and BRCA2 mutation carriers
    Jane C. Figueiredo
    Robert W. Haile
    Jonine L. Bernstein
    [J]. Current Breast Cancer Reports, 2009, 1 (3) : 139 - 147
  • [28] Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers
    Milne, Roger L.
    Osorio, Ana
    Ramon y Cajal, Teresa
    Baiget, Montserrat
    Lasa, Adriana
    Diaz-Rubio, Eduardo
    de la Hoya, Miguel
    Caldes, Trinidad
    Teule, Alex
    Lazaro, Conxi
    Blanco, Ignacio
    Balmana, Judith
    Sanchez-Olle, Gessami
    Vega, Ana
    Blanco, Ana
    Chirivella, Isabel
    Esteban Cardenosa, Eva
    Duran, Mercedes
    Velasco, Eladio
    Martinez de Duenas, Eduardo
    Tejada, Maria-Isabel
    Miramar, Maria-Dolores
    Calvo, Maria-Teresa
    Guillen-Ponce, Carmen
    Salazar, Raquel
    San Roman, Carlos
    Urioste, Miguel
    Benitez, Javier
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (01) : 221 - 232
  • [29] Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
    Narod, SA
    Dubé, MP
    Klijn, J
    Lubinski, J
    Lynch, HT
    Ghadirian, P
    Provencher, D
    Heimdal, K
    Moller, P
    Robson, M
    Offit, K
    Isaacs, C
    Weber, B
    Friedman, E
    Gershoni-Baruch, R
    Rennert, G
    Pasini, B
    Wagner, T
    Daly, M
    Garber, JE
    Neuhausen, SL
    Ainsworth, P
    Olsson, H
    Evans, G
    Osborne, M
    Couch, F
    Foulkes, WD
    Warner, E
    Kim-Sing, C
    Olopade, O
    Tung, N
    Saal, HM
    Weitzel, J
    Merajver, S
    Gauthier-Villars, M
    Jernstrom, H
    Sun, P
    Brunet, JS
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (23) : 1773 - 1779
  • [30] Breast cancer risk among male BRCA1 and BRCA2 mutation carriers
    Tai, Yu Chuan
    Domchek, Susan
    Parmigiani, Giovanni
    Chen, Sining
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (23) : 1811 - 1814